Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued: 2017-2024

Historic Shares Issued for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $970.0 million.

  • Crinetics Pharmaceuticals' Shares Issued fell 93.59% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 16.62%. This contributed to the annual value of $970.0 million for FY2024, which is 162.87% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Shares Issued of $970.0 million as of FY2024, which was up 162.87% from $369.0 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Issued peaked at $970.0 million during FY2024, and registered a low of $114.3 million during FY2020.
  • Its 3-year average for Shares Issued is $485.4 million, with a median of $369.0 million in 2023.
  • In the last 5 years, Crinetics Pharmaceuticals' Shares Issued skyrocketed by 90,600.79% in 2020 and then plummeted by 53.02% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Issued (Yearly) stood at $114.3 million in 2020, then spiked by 118.35% to $249.5 million in 2021, then tumbled by 53.02% to $117.2 million in 2022, then soared by 214.75% to $369.0 million in 2023, then spiked by 162.87% to $970.0 million in 2024.